Insider Transactions

Medtronic plc (MDT) Insider Transactions

Over the last 12 months, 20 Medtronic plc (MDT) insiders filed 144 SEC Form 4 transactions — $462.8K in open-market purchases ( 1 distinct buyers) and $9.3M in open-market sales. 0% of all transactions were executed under a pre-scheduled Rule 10b5-1 trading plan.

Recent Form 4 Filings Most recent 50 of 144 (1-year window)

Each row is a single Form 4 filing event for MDT, sourced directly from SEC EDGAR. The Type column classifies the SEC transaction code into Buy / Sell / Grant / Exercise / Other; the 10b5-1 badge marks trades executed under a pre-scheduled SEC Rule 10b5-1 plan.

Date Insider Title Type SEC Code Value Shares Price
2026-06-08 KIIL HARRY SKIP EVP & President Cardiovascular Sell S $318.6K 3,961 $80.44
2026-06-08 KIIL HARRY SKIP EVP & President Cardiovascular Sell S $18.3K 228 $80.45
2026-06-05 Blomquist Denise L. Chief Accounting Officer Other F $19.7K 237 $83.32
2026-06-04 KIIL HARRY SKIP EVP & President Cardiovascular Other F $568.0K 6,817 $83.32
2026-06-04 Martha Geoffrey Chairman and CEO Other F $3.5M 41,936 $83.32
2026-06-04 Marinaro Michael EVP, Pres MedSurg and Americas Other F $622.5K 7,471 $83.32
2026-06-04 Walter Matthew R. SVP, Chief HR Officer Other F $236.6K 2,840 $83.32
2026-05-26 Walter Matthew R. SVP, Chief HR Officer Exercise M $0 9,149 $0.00
2026-05-26 Walter Matthew R. SVP, Chief HR Officer Exercise M $0 8,449 $0.00
2026-05-26 Wall Brett A. EVP & Pres Neuroscience Exercise M $0 26,907 $0.00
2026-05-26 Wall Brett A. EVP & Pres Neuroscience Exercise M $0 24,214 $0.00
2026-05-26 Martha Geoffrey Chairman and CEO Exercise M $0 94,963 $0.00
2026-05-26 Martha Geoffrey Chairman and CEO Exercise M $0 85,461 $0.00
2026-05-26 Marinaro Michael EVP, Pres MedSurg and Americas Exercise M $0 18,994 $0.00
2026-05-26 Marinaro Michael EVP, Pres MedSurg and Americas Exercise M $0 17,093 $0.00
2026-05-26 KIIL HARRY SKIP EVP & President Cardiovascular Exercise M $0 15,195 $0.00
2026-05-26 KIIL HARRY SKIP EVP & President Cardiovascular Exercise M $0 14,517 $0.00
2026-05-26 Blomquist Denise L. Chief Accounting Officer Exercise M $0 1,712 $0.00
2026-05-26 Blomquist Denise L. Chief Accounting Officer Exercise M $0 1,621 $0.00
2026-05-01 Walter Matthew R. SVP, Chief HR Officer Other F $2.8K 35 $80.00
2026-04-28 Blomquist Denise L. Chief Accounting Officer Other F $26.0K 318 $81.90
2026-04-28 Powell Kendall J Other F $17.0K 207 $81.90
2026-04-28 NABEL ELIZABETH G Other F $17.0K 207 $81.90
2026-04-28 Lofton Kevin E Other F $17.0K 207 $81.90
2026-04-28 Lewis Gregory P Other F $17.0K 207 $81.90
2026-04-28 HOGAN RANDALL J Other F $17.0K 207 $81.90
2026-04-28 Fonseca Lidia Other F $17.0K 207 $81.90
2026-04-28 DONNELLY SCOTT C Other F $17.0K 207 $81.90
2026-04-28 ARNOLD CRAIG Other F $17.0K 207 $81.90
2026-04-27 Blomquist Denise L. Chief Accounting Officer Grant A $0 1,508 $0.00
2026-04-27 Powell Kendall J Grant A $0 2,111 $0.00
2026-04-27 NABEL ELIZABETH G Grant A $0 2,111 $0.00
2026-04-27 Lofton Kevin E Grant A $0 2,111 $0.00
2026-04-27 Lewis Gregory P Grant A $0 2,111 $0.00
2026-04-27 Lee Joon Sup Grant A $0 1,803 $0.00
2026-04-27 Jellison William R Grant A $0 1,444 $0.00
2026-04-27 HOGAN RANDALL J Grant A $0 2,111 $0.00
2026-04-27 Groetelaars John P Grant A $0 1,444 $0.00
2026-04-27 Fonseca Lidia Grant A $0 2,111 $0.00
2026-04-27 DONNELLY SCOTT C Grant A $0 2,111 $0.00
2026-04-27 ARNOLD CRAIG Grant A $0 2,111 $0.00
2026-03-03 Pieton Thierry EVP & Chief Financial Officer Grant $287.8K 2,976 $96.71
2026-02-20 Blomquist Denise L. Chief Accounting Officer Grant $0 340 $0.00
2026-02-19 KIIL HARRY SKIP EVP & President Cardiovascular Grant $2.8M 30,568 $93.08
2026-02-19 KIIL HARRY SKIP EVP & President Cardiovascular Grant $1.7M 19,923 $87.76
2026-02-19 KIIL HARRY SKIP EVP & President Cardiovascular Grant $30.8K 385 $80.00
2026-02-19 KIIL HARRY SKIP EVP & President Cardiovascular Grant $0 30,568 $0.00
2026-02-19 KIIL HARRY SKIP EVP & President Cardiovascular Grant $0 19,923 $0.00
2026-02-19 KIIL HARRY SKIP EVP & President Cardiovascular Grant $0 385 $0.00
2026-02-19 KIIL HARRY SKIP EVP & President Cardiovascular Sell $161.3K 1,648 $97.86

Showing the most recent 50 of 144 transactions. For the full 1-year history with sorting, filtering, and cross-ticker industry context, open the full insider transactions drilldown.

Top Insider Buyers of MDT By dollar volume, 1-year window

  1. Jellison William R $462.8K

Methodology & FAQ

How We Track MDT Insider Transactions

Form 4 disclosures are sourced directly from SEC EDGAR and re-ingested on every pipeline cycle. A complete description of transaction-code handling, the open-market vs grant distinction, and the Rule 10b5-1 plan-reference heuristic is documented in the Methodology.

What is an SEC Form 4 filing for Medtronic plc?

Form 4 is a transaction-level disclosure that corporate insiders — officers, directors, and beneficial owners of more than 10% of a registered class of equity securities — must file with the SEC within two business days of any change in their beneficial ownership of Medtronic plc (MDT) shares.

What is a Rule 10b5-1 trading plan?

Rule 10b5-1 is an SEC rule that lets insiders schedule trades in advance under a written plan, providing an affirmative defense against insider-trading allegations as long as the plan was adopted in good faith and not while in possession of material non-public information. Form 4 rows marked "10b5-1" on this page indicate the underlying trade was executed under such a plan; rows without the badge are discretionary or did not reference a plan in the Form 4 footnotes.

How is "insider buying" different from a stock grant or option exercise?

An insider buy (SEC transaction code P) is an open-market purchase of Medtronic plc (MDT) stock executed at the prevailing market price using the insider's personal capital. Stock grants (code A) and option exercises (code M) are compensation events, not directional trades; they are tracked separately and excluded from the "conviction" signal because they are not discretionary purchases.

How recent is the data?

Form 4 transactions are typically reported within two business days of execution. Pactolio re-ingests the EDGAR feed on a nightly cycle and reflects new filings on the next ingest run, typically within 24 hours of EDGAR acceptance. The table on this page covers the most recent 1-year window.